Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma

P G Pelicci, D M Knowles 2nd, I Magrath, R Dalla-Favera, P G Pelicci, D M Knowles 2nd, I Magrath, R Dalla-Favera

Abstract

We have examined the position of the chromosomal breakpoint relative to the human c-myc gene (MYC) and the presence of other structural alterations of the same locus in 19 fresh samples of Burkitt lymphoma (BL) and 13 BL-derived cell lines. This panel includes the two pathogenetic forms of BL: the endemic (African-type) BL (eBL) and sporadic (American-type) BL (sBL). In all cases tested, including fresh samples and cell lines, structural alterations of the 5' portion of the gene were detected, suggesting that they may be necessary for c-myc activation. However, the site of chromosomal breakpoint and the type of structural alterations differ in eBL and sBL. In 16 of 18 sBL cases, chromosomal translocation truncates the gene within a 5' region that includes the first intron, the first exon, and 5' flanking sequences. Conversely, in 14 of 14 eBL samples, the chromosomal breakpoint is located outside the c-myc locus, yet the same 5' sequences are affected by several mutations identifiable by restriction enzyme polymorphisms. Different genetic mechanisms may therefore be involved in chromosomal translocation/c-myc activation, and these differences may be a function of differences in the stage of differentiation of eBL versus sBL.

References

    1. J Natl Cancer Inst. 1980 Mar;64(3):477-83
    1. Cell. 1985 Sep;42(2):589-97
    1. N Engl J Med. 1981 Sep 24;305(13):735-45
    1. Nature. 1982 Jul 29;298(5873):474-6
    1. J Immunol. 1982 Sep;129(3):1336-42
    1. Nature. 1982 Sep 2;299(5878):61-3
    1. Proc Natl Acad Sci U S A. 1982 Jul;79(13):4175-9
    1. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6497-501
    1. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7
    1. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7837-41
    1. Science. 1983 Feb 25;219(4587):963-7
    1. Cell. 1982 Dec;31(2 Pt 1):443-52
    1. Cell. 1983 Oct;34(3):779-87
    1. Science. 1983 Nov 18;222(4625):765-71
    1. Cell. 1983 Dec;35(3 Pt 2):603-10
    1. Nature. 1983 Dec 22-1984 Jan 4;306(5945):799-803
    1. Cell. 1984 Feb;36(2):339-48
    1. Nature. 1984 Jan 26-Feb 1;307(5949):334-40
    1. Lancet. 1984 Mar 31;1(8379):745-6
    1. Cell. 1984 Jun;37(2):511-20
    1. Proc Natl Acad Sci U S A. 1984 Nov;81(21):6798-802
    1. Blood. 1985 Jan;65(1):1-7
    1. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2315-9
    1. Ann Intern Med. 1981 Feb;94(2):218-35

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere